Sept.19, 2022

Dear Healthcare Provider,

You are reading this because your patient has reached out to CLL Society requesting assistance in obtaining access to Evusheld, a vital COVID-19 preventative medication approved only for those immunocompromised.

The CLL Society believes that Evusheld (tixagevimab co-packaged with cilgavimab) is an appropriate choice for all chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients, regardless of their treatment status. This is consistent with NIH, CDC, and FDA guidelines.

As you know, Evusheld is the only FDA Emergency Use Authorized (EUA) Pre-Exposure Prophylaxis (PrEP) monoclonal antibody option for SARS-CoV-2 prevention in the high-risk immunocompromised population, which includes all those with CLL and SLL.

At the request of the Office of the Assistant Secretary for Preparedness and Response (ASPR), which is the branch of Health and Human Services (HHS) that is responsible for the government’s management of the COVID-19 pandemic, CLL Society joined in a pilot program to help more eligible patients gain equitable access to Evusheld that has been expanded across the nation.

Now that Evusheld doses are readily available in the US, we are excited to announce that an additional short and simple mechanism for ordering Evusheld is being made available.

The new ordering mechanism is intended only for individual healthcare providers. This is not for larger practices associated with academic institutions/cancer centers, which are still expected to have their associated pharmacies work with the state health departments to utilize the HHS ordering portal (HPOP) for bulk Evusheld orders. Anyone already registered in HPOP should continue using that mechanism to order Evusheld. This mechanism is specifically for any healthcare providers who wish to order 1-2 doses in small quantities to administer to their patient(s).

Ordering information:
• See www.orderevusheld.com, which redirects to the AmerisourceBergen simple one-page order form: https://app.smartsheet.com/b/form/21e4312a2985457f982bb2738cf82744.
• For specific questions related to ordering, email c19therapies@amerisourcebergen.com.

Thank you for considering this powerful and free monoclonal antibody option for your most vulnerable patients who may not be well protected from COVID-19 by vaccination alone.

Kind regards,

Brian Koffman, MDCM (retired), MS Ed
Co-Founder, Executive VP, and Chief Medical Officer
CLL Society, Inc.
949-463-6533